Going global: the adoption of the World Health Organization’s enabling recommendation on oral pre-exposure prophylaxis for HIV
Ioannis Hodges-Mameletzis A C , Shona Dalal A , Busisiwe Msimanga-Radebe B , Michelle Rodolph A and Rachel Baggaley A
+ Author Affiliations
- Author Affiliations
A World Health Organization, Headquarters, Avenue Appia 20, 1202 Geneva, Switzerland.
B World Health Organization, South Africa Country Office, 7th Floor Metro Park Building, 351 Francis Baard Street, Pretoria, 0002, South Africa.
C Corresponding author. Email: yanni.hodges@gmail.com
Sexual Health 15(6) 489-500 https://doi.org/10.1071/SH18125
Submitted: 29 June 2018 Accepted: 8 October 2018 Published: 29 November 2018
Journal Compilation © CSIRO 2018 Open Access CC BY-NC-ND
Abstract
In September 2015, the World Health Organization (WHO) launched evidence-based guidelines by recommending that any person at substantial HIV risk should be offered oral pre-exposure prophylaxis (PrEP) containing tenofovir disoproxil fumarate (TDF) as an additional prevention choice. Since 2017, PrEP medicines have also been listed in the WHO’s Essential Medicines List, including TDF/emtricitabine (FTC) and TDF in combination with lamivudine (3TC). A descriptive policy review and analysis of countries adopting WHO’s 2015 recommendation on oral PrEP was conducted. As of June 2018, we identified 35 countries that had some type of policy on oral PrEP, and an additional five countries where a specific policy on PrEP is currently pending. A total of 19 high-income countries (HICs) and 21 low- and middle-income countries (LMICs) have adopted or have a pending policy. Most countries that have adopted or pending PrEP are in the European (42.9%) or African (30.0%) region. TDF/FTC is the most commonly recommended PrEP drug in the guidelines reviewed, although seven countries, namely in sub-Saharan Africa (6/7), are also recommending the use of TDF/3TC for PrEP. In sum, by the end of 2018, at least 40 countries (20.6%) are anticipated to have adopted WHO’s oral PrEP recommendation. Nonetheless, policy uptake does not reflect broader programmatic coverage of PrEP services, which remain limited across all settings, irrespective of income status. Enhancing global partnerships is needed to support and track ongoing policy adoption and to ensure that policy is translated into meaningful implementation of PrEP services.
Additional keywords: antiretroviral, policy, PrEP, prevention.
References
[1] Baggaley R, Dalal S, Johnson C, Macdonald V, Mameletzis I, Rodolph M, Figueroa C, Samuelson J, Verster A, Doherty M, Hirnschall G. Beyond the 90-90-90: refocusing HIV prevention as part of the global HIV response. J Int AIDS Soc 2016; 19 21348| Beyond the 90-90-90: refocusing HIV prevention as part of the global HIV response.Crossref | GoogleScholarGoogle Scholar |
[2] Heffron R, Ngure K, Odoyo J, Bulya N, Tindimwebwa E, Hong T, Kidoguchi L, Donnell D, Mugo NR, Bukusi EA, Katabira E, Asiimwe S, Morton J, Morrison S, Haugen H, Mujugira A, Haberer JE, Ware NC, Wyatt MA, Marzinke MA, Frenkel LM, Celum C, Baeten JM, Partners Demonstration Project Team. Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. Gates Open Res. 2018; 1 3
| Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa.Crossref | GoogleScholarGoogle Scholar |
[3] Hallett TB, Baeten JM, Heffron R, Barnabas R, De Bruyn G, Cremin Í, Delany S, Garnett GP, Gray G, Johnson L, McIntyre J, Rees H, Celum C. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8 e1001123
| Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.Crossref | GoogleScholarGoogle Scholar |
[4] Dehne KL, Dallabetta G, Wilson D, Garnett GP, Laga M, Benomar E, Fakoya A, Baggaley RC, Nelson LJ, Kasedde S, Bermejo A, Warren M, Benedikt C, Global Prevention Focal Point Group. HIV Prevention 2020: a framework for delivery and a call for action. Lancet HIV 2016; 3 e323–32.
| HIV Prevention 2020: a framework for delivery and a call for action.Crossref | GoogleScholarGoogle Scholar |
[5] World Health Organization. Global Health Sector Strategy on HIV 2016–2021. Geneva: World Health Organization; 2016.
[6] Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2018. Geneva: UNAIDS; 2018. Available online at: http://www.unaids.org/en/resources/documents/2018/unaids-data-2018 [verified 1 November 2018].
[7] European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS Surveillance in Europe 2017–2016 Data. Stockholm: ECDC; 2017.
[8] Lam CR, Holtz TH, Leelawiwat W, Mock PA, Chonwattana W, Wimonsate W, Varangrat A, Thienkrua W, Rose C, Chitwarakorn A, Curlin ME. Subtypes and risk behaviors among incident HIV cases in the Bangkok Men Who Have Sex With Men Cohort Study, Thailand, 2006-2014. AIDS Res Hum Retroviruses 2017; 33 1004–12.
| Subtypes and risk behaviors among incident HIV cases in the Bangkok Men Who Have Sex With Men Cohort Study, Thailand, 2006-2014.Crossref | GoogleScholarGoogle Scholar |
[9] Ross AG, Ditangco RA, Belimac JG, Olveda RM, Mercado ES, Chau TN, Crowe SM. The dire sexual health crisis among MSM in the Philippines: an exploding HIV epidemic in the absence of essential health services. Int J Infect Dis 2015; 37 6–8.
| The dire sexual health crisis among MSM in the Philippines: an exploding HIV epidemic in the absence of essential health services.Crossref | GoogleScholarGoogle Scholar |
[10] Thienkrua W, van Griensven F, Mock PA, Dunne EF, Raengsakulrach B, Wimonsate W, Howteerakul N, Ungsedhapand C, Chiwarakorn A, Holtz TH. Young men who have sex with men at high risk for HIV, Bangkok MSM Cohort Study, Thailand 2006–2014. AIDS Behav 2018; 22 2137–46.
| Young men who have sex with men at high risk for HIV, Bangkok MSM Cohort Study, Thailand 2006–2014.Crossref | GoogleScholarGoogle Scholar |
[11] van Griensven F, Guadamuz TE, de Lind van Wijngaarden JW, Phanuphak N, Solomon SS, Lo Y-R. Challenges and emerging opportunities for the HIV prevention, treatment and care cascade in men who have sex with men in Asia Pacific. Sex Transm Infect 2017; 93 356–62.
| Challenges and emerging opportunities for the HIV prevention, treatment and care cascade in men who have sex with men in Asia Pacific.Crossref | GoogleScholarGoogle Scholar |
[12] De Boni R, Veloso VG, Grinsztejn B. Epidemiology of HIV in Latin America and the Caribbean. Curr Opin HIV AIDS 2014; 9 192–8.
| Epidemiology of HIV in Latin America and the Caribbean.Crossref | GoogleScholarGoogle Scholar |
[13] Rasmussen D, Wilkinson E, Vandormael A, Tanser F, Pillay D, Stadler T, de Oliveira T. External introductions helped drive and sustain the high incidence of HIV-1 in rural KwaZulu-Natal, South Africa. bioRxiv 2017; 119826
| External introductions helped drive and sustain the high incidence of HIV-1 in rural KwaZulu-Natal, South Africa.Crossref | GoogleScholarGoogle Scholar |
[14] Justman J, Reed JB, Bicego G, Donnell D, Li K, Bock N, Koler A, Philip NM, Mlambo CK, Parekh BS, Duong YT, Ellenberger DL, El-Sadr WM, Nkambule R. Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study. Lancet HIV 2017; 4 e83–92.
| Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study.Crossref | GoogleScholarGoogle Scholar |
[15] Thomson KA, Hughes J, Baeten JM, John-Stewart G, Celum C, Cohen CR, Ngure K, Kiarie J, Mugo N, Heffron R. Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners. J Infect Dis 2018; 218 16–25.
| Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners.Crossref | GoogleScholarGoogle Scholar |
[16] Kamarulzaman A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K, Moazen B, Wirtz AL, Verster A, Altice FL. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet 2016; 388 1115–26.
| Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners.Crossref | GoogleScholarGoogle Scholar |
[17] World Health Organization. WHO Handbook for Guideline Development, 2nd edn. Geneva: World Health Organization; 2014.
[18] World Health Organization. Guidance on pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk for HIV: recommendations for use in the context of demonstration projects. Geneva: World Health Organization; 2012.
[19] World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2014.
[20] Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, et al Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363 2587–99.
| Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.Crossref | GoogleScholarGoogle Scholar |
[21] McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie N, Bowman C, Lacey CJ, Apea V, Brady M, Fox J, Taylor S, Antonucci S, Khoo SH, Rooney J, Nardone A, Fisher M, McOwan A, Phillips AN, Johnson AM, Gazzard B, Gill ON. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016; 387 53–60.
| Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.Crossref | GoogleScholarGoogle Scholar |
[22] Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, et al On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015; 373 2237–46.
| On-demand preexposure prophylaxis in men at high risk for HIV-1 infection.Crossref | GoogleScholarGoogle Scholar |
[23] Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, Rodolph M, Hodges-Mameletzis I, Grant RM. Effectiveness and safety of oral HIV pre-exposure prophylaxis (PrEP) for all populations: a systematic review and meta-analysis. AIDS 2016; 30 1973–83.
| Effectiveness and safety of oral HIV pre-exposure prophylaxis (PrEP) for all populations: a systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar |
[24] World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015.
[25] World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2016.
[26] World Health Organization. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. Geneva: World Health Organization; 2017.
[27] Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011; 60 65–8.
[28] Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2014: a clinical practice guideline. Atlanta: CDC; 2014.
[29] Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2017 update: a clinical practice guideline. Atlanta: CDC; 2018. Available online at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf [verified 1 November 2018].
[30] European AIDS Clinical Society. European AIDS Clinical Society Treatment Guidelines, 2016. Brussels: EACS; 2016. Available online at: http://www.eacsociety.org/files/guidelines_8.1-english.pdf [verified 1 November 2018].
[31] European AIDS Clinical Society. European AIDS Clinical Society Treatment Guidelines, 2017. Brussels: EACS; 2017. Available online at: http://www.eacsociety.org/files/guidelines_9.0-english.pdf [verified 1 November 2018].
[32] European AIDS Clinical Society. Clinical Management of HIV PrEP Online Course. Brussels: EACS; 2018. Available online at: http://www.eacsociety.org/education/clinical-management-of-hiv-online-course/clinical-management-of-hiv-online-course.html [verified 23 October 2018].
[33] Southern African HIV Clinicians Society Consensus Committee. Southern African guidelines for the safe use of pre-exposure prophylaxis in men who have sex with men who are at risk for HIV infection. South Afr J HIV Med 2012; 13 40–55.
[34] Bekker LG, Rebe K, Venter F, Maartens G, Moorhouse M, Conradie F, Wallis C, Black V, Harley B, Eakles R. Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. South Afr J HIV Med 2016; 17 455
[35] Wright E, Grulich A, Roy K, Boyd M, Cornelisse V, Russell D, O’Donnell D, Whittaker B, Crooks L, Zablotska I. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. J Virus Erad 2017; 3 168–84.
[36] Wright E, Grulich A, Roy K, Boyd M, Cornelisse V, Russell D, O’Donnell D, Whittaker B, Crooks L, Zablotska I. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018. J Virus Erad 2018; 4 143–59.
[37] National Agency for Research on AIDS and Viral Hepatitis (ANRS). Medical care of people living with HIV - prevention and screening (April 2018). Paris: The National Council on AIDS and viral hepatitis (CNS); 2018. Available online at: https://cns.sante.fr/wp-content/uploads/2018/04/experts-vih_prevention-depistage.pdf [verified 1 November 2018]. [In French]
[38] Swiss Federal Commission for Sexual Health (FCSH). Recommendations of the FCSH on pre-exposure prophylaxis (PrEP) for HIV prevention. Bern: Federal Office of Public Health; 2016. Available online at: https://www.bag.admin.ch/dam/bag/en/dokumente/ mt/p-und-p/richtlinien-empfehlungen/prep-empfehlungen-der-eksg-januar-2016.pdf.download.pdf/fcsh-recommendations-prep-hiv.pdf [verified 1 November 2018].
[39] Grant RM, Glidden DV. HIV moments and pre-exposure prophylaxis. Lancet 2016; 387 1507–8.
| HIV moments and pre-exposure prophylaxis.Crossref | GoogleScholarGoogle Scholar |
[40] World Health Organization. WHO Model List of Essential Medicines: 20th List (March 2017). Geneva: World Health Organization; 2017. Available online at: http://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf?ua=1 [verified 23 October 2018].
[41] Ford N, Mayer KH, World Health Organization Postexposure Prophylaxis Guideline Development Group World Health Organization guidelines on postexposure prophylaxis for HIV: recommendations for a public health approach. Clin Infect Dis 2015; 60 S161–4.
| World Health Organization guidelines on postexposure prophylaxis for HIV: recommendations for a public health approach.Crossref | GoogleScholarGoogle Scholar |
[42] British HIV Association. Update of BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP), 2018. London: British HIV Association; 2018. Available online at: https://www.bhiva.org/file/5b729cd592060/2018-PrEP-Guidelines.pdf [verified 23 October 2018].
[43] World Health Organization. Preventing HIV during pregnancy and breastfeeding in the context of PrEP – technical brief. Geneva: World Health Organization; 2017. Available online at: http://apps.who.int/iris/bitstream/handle/10665/255866/WHO-HIV-2017.09-eng.pdf;jsessionid=3F00F80ECAA456FA41F786522011E0E3?sequence=1 [verified 1 November 2018].
[44] Ministry of Health, National AIDS & STI Control Programme. Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya, 2016 edn. Nairobi, Kenya: NASCOP; 2016. Available online at: https://aidsfree.usaid.gov/sites/default/files/kenya_art_2016.pdf [verified 23 October 2018].
[45] AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Consensus document on control and monitoring of HIV infection, 2018. Madrid: GeSIDA; 2018. [In Spanish]
[46] Department of Quality in Health, Portuguese National Program for HIV, AIDS and Tuberculosis. Pre-exposure prophylaxis of HIV infection in adults. Lisbon: Department of Quality in Health, Portuguese National Program for HIV, AIDS and Tuberculosis; 2017. [In Portuguese]
[47] Taiwan AIDS Society. Guidelines for use of PrEP in Taiwan. Taipei: Taiwan AIDS Society; 2018.
[48] World Health Organization. Global Health Sector Strategy on Sexually Transmitted Infections, 2016–2021. Geneva: World Health Organization; 2016. Available online at: http://apps.who.int/iris/bitstream/handle/10665/246296/WHO-RHR-16.09-eng.pdf;jsessionid= 83B1BDB16B0097FA7E9E10C35C775C44?sequence=1 [verified 23 October 2018].
[49] World Health Organization. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection – clinical module. Geneva: World Health Organization; 2017. Available online at: http://apps.who.int/iris/bitstream/handle/10665/255889/WHO-HIV-2017.17-eng.pdf?sequence=1 [verified 23 October 2018].
[50] United States Food and Drug Administration. Approval letter for adolescent indication. Rockville: United States Food and Drug Administration; 2018. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/021752Orig1s055ltr.pdf [verified 23 October 2018].
[51] European Medicines Agency. Summary of opinion on Truvada. London: European Medicines Agency; 2017. Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_ of_opinion/human/000594/WC500240366.pdf [verified 23 October 2018].
[52] Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, Harris DR, Mulligan K, Zimet G, Mayer KH, Anderson P, Kiser JJ, Lally M, Brothers J, Bojan K, Rooney J, Wilson CM. Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatr 2017; 171 1063–71.
| Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States.Crossref | GoogleScholarGoogle Scholar |
[53] Machado DM, de Sant’Anna Carvalho AM, Riera R. Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives. Adolesc Health Med Ther 2017; 8 137–48.
| Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives.Crossref | GoogleScholarGoogle Scholar |
[54] Coleman R, Prins M. Options for affordable pre-exposure prophylaxis (PrEP) in national HIV prevention programmes in Europe. Euro Surveill 2017; 22 17-00698
| Options for affordable pre-exposure prophylaxis (PrEP) in national HIV prevention programmes in Europe.Crossref | GoogleScholarGoogle Scholar |
[55] Prepster. Prepster. London: Prepster; 2018. Available online at: http://prepster.info/pdf [verified 23 October 2018].
[56] HIV i-Base. UK guide to PrEP. London: HIV i-Base; 2018. Available online at: http://i-base.info/guides/prep [verified 23 October 2018].
[57] AIDES. La PrEP. Paris: AIDES; 2018. Available online at: https://www.aides.org/prep [verified 23 October 2018].
[58] Public Health England. PrEP impact trial protocol. London: Public Health England; 2017. Available online at: https://docs.wixstatic.com/ugd/f75c00_f1c229feb1f1471189bc99c9d697b0e5.pdf [verified 23 October 2018].
[59] PrEP in Europe. PrEP in Europe summit. London: PrEP in Europe; 2018. Available online at: http://www.prepineurope.org/en/summit [verified 23 October 2018].
[60] United States Food and Drug Administration. Truvada PrEP indication approval. Rockville: United States Food and Drug Administration; 2012. Available online at: https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM312290.pdf [verified 23 October 2018].
[61] World Health Organization, HIV Department. Internal records. Geneva: World Health Organization; 2018.
[62] European Medicines Agency. Truvada PrEP indication approval. London: European Medicines Agency; 2016. Available online at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/07/news_detail_002578.jsp&mid=WC0b01ac058004d5c1 [verified 23 October 2018].
[63] National Department of Health, Republic of South Africa. National Policy on HIV Pre-exposure Prophylaxis (PrEP) and Test and Treat (T&T). Pretoria: National Department of Health, Republic of South Africa; 2016. Available online at: http://www.sahivsoc.org/Files/PREP%20and%20TT%20Policy%20-%20Final%20Draft%20-%205%20May%202016%20(HIV%20news).pdf [verified 23 October 2018].
[64] Ford N, Vitoria M, Doherty M. Providing antiretroviral therapy to all who are HIV positive: the clinical, public health and programmatic benefits of Treat All. J Int AIDS Soc 2018; 21 e25078
| Providing antiretroviral therapy to all who are HIV positive: the clinical, public health and programmatic benefits of Treat All.Crossref | GoogleScholarGoogle Scholar |
[65] National AIDS & STI Control Programme (NASCOP), Ministry of Health. Framework for the Implementation of Pre-exposure Prophylaxis of HIV in Kenya. Nairobi, Kenya: NASCOP; 2017.
[66] Federal University of Minas Gerais Medical School. Pesquisa vai comparar efeitos da PrEP importada com a nacional. Belo Horizonte: Federal University of Minas Gerais Medical School; 2018. Available online at: https://site.medicina.ufmg.br/inicial/pesquisa-vai-comparar-efeitos-da-prep-importada-com-a-nacional/ [verified 23 October 2018]. [In Portuguese]
[67] US National Library of Medicine. Prevenir protocol, identifier NCT03113123. Bethesda: US National Library of Medicine; 2017. Available online at: https://clinicaltrials.gov/ct2/show/NCT03113123 [verified 23 October 2018].
[68] Molina JM, Ghosn J, Béniguel L, Rojas-Castro D, Algarte-Genin M, Pialoux G, Delaugerre C, Yazdanpanah Y, Katlama C, Ségouin C, Morel S, Pintado C, Loze B, Le Mestre S, Gibowski S, Dore V, Assoumou L, Spire B, Costagliola D, Prévenir ANRS study group. Incidence of HIV-infection in the ANRS Prévenir study in Paris region with daily or on-demand PrEP with TDF/FTC. Proceedings of the 22nd International AIDS Conference (AIDS 2018); 23–27 July 2018; Amsterdam, Netherlands. Geneva: AIDS 2018; 2018. Abstract WEAE0406LB. Available online at: http://programme.aids2018.org/Abstract/Abstract/13278 [verified 23 October 2018].
[69] World Health Organization. WHO Global Price Reporting Mechanism; 2018. Geneva: World Health Organization; 2018.
[70] Pillay Y. South Africa’s experience in bringing PrEP to scale for a range of populations. Proceedings of the 9th International AIDS Society (IAS) Conference; 23–26 July 2017; Paris, France. Geneva: IAS; 2017. Abstract SUSA0703.
[71] San Francisco City Health Department. Annual HIV epidemiological report. San Francisco: San Francisco City Health Department; 2017.
[72] New York City Department of Health and Mental Hygiene, HIV Epidemiology and Field Services Program. HIV surveillance annual report, 2016. New York, NY: New York City Department of Health and Mental Hygiene; 2017. Available online at: https://www1.nyc.gov/assets/doh/downloads/pdf/dires/hiv-surveillance-annualreport-2016.pdf [verified 9 November 2018].
[73] Grulich AE, Guy R, Amin J, Jin F, Selvey C, Holden J, Schmidt HA, Zablotska I, Price K, Whittaker B, Chant K, Cooper C, McGill S, Telfer B, Yeung B, Levitt G, Ogilvie EE, Dharan NJ, Hammoud MA, Vaccher S, et al Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV 2018;
| Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.Crossref | GoogleScholarGoogle Scholar |
[74] Nwokolo N, Hill A, McOwan A, Pozniak A. Rapidly declining HIV infection in MSM in central London. Lancet HIV 2017; 4 e482–3.
| Rapidly declining HIV infection in MSM in central London.Crossref | GoogleScholarGoogle Scholar |
[75] Pharmaceutical Benefits Scheme (PBS), Australian Government Department of Health. December 2017 decision of PrEP. Canberra: Commonwealth of Australia; 2017. Available online at: https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2017-12/files/tenofovir-emtricitabine-prep-psd-december-2017.docx [verified 23 October 2018].
[76] Delanoe C, Coulomb D. French announcement for PrEP coverage, November, 23, 2015. Malakoff: Le Quotidien du Médecin; 2015. Available online at: https://www.lequotidiendumedecin.fr/actualites/article/2015/11/23/marisol-touraine-dit-oui-la-prep-et-annonce-son-remboursement-en-france-en-janvier-2016_782261 [verified 23 October 2018].
[77] World Health Organization. Global PrEP Coalition. Geneva: World Health Organization; 2018. Available online at: http://www.who.int/hiv/prep/global-prep-coalition/ [verified 23 October 2018].
[78] Kim SC, Becker S, Dieffenbach C, Hanewall BS, Hankins C, Lo Y-R, Mellors JW, O’Reilly K, Paxton L, Roffenbender JS, Warren M, Piot P, Dybul MR. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc 2010; 13 24
| Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities.Crossref | GoogleScholarGoogle Scholar |
